Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug

Carfilzomib is a last generation proteasome inhibitor (PI) with proven clinical efficacy in the treatment of relapsed/refractory multiple myeloma. This drug is considered to be extremely specific in inhibiting the chymotrypsin-like activity of the 20S proteasome, encoded by the β5 subunit, overcomin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tundo, Grazia Raffaella, Sbardella, Diego, Oddone, Francesco, Grasso, Giuseppe, Marini, Stefano, Atzori, Maria Grazia, Santoro, Anna Maria, Milardi, Danilo, Bellia, Francesco, Macari, Gabriele, Graziani, Grazia, Polticelli, Fabio, Cascio, Paolo, Parravano, Mariacristina, Coletta, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869475/
https://www.ncbi.nlm.nih.gov/pubmed/35204815
http://dx.doi.org/10.3390/biom12020315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869475/
https://www.ncbi.nlm.nih.gov/pubmed/35204815
http://dx.doi.org/10.3390/biom12020315

Ejemplares similares